Alaethes Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Alaethes Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.76M	Buy	3,949 +162	+4%	+$75.5K	0.5%	66
2025 Q4	$1.72M	Sell	3,787 -167	-4%	-$72K	0.48%	65
2025 Q3	$1.55M	Buy	3,954 +745	+23%	+$311K	0.44%	77
2025 Q2	$1.43M	Buy	3,209 +158	+5%	+$72.8K	0.43%	78
2025 Q1	$1.48M	Buy	+3,051	New	+$1.42M	0.54%	71
2022 Q2	–	Sell	-22	Closed	-$6K	–	284
2022 Q1	$6K	Hold	22	–	–	﹤0.01%	255
2021 Q4	$5K	Hold	22	–	–	﹤0.01%	238
2021 Q3	$4K	Hold	22	–	–	﹤0.01%	231
2021 Q2	$4K	Buy	+22	New	+$4.6K	﹤0.01%	224

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Alaethes Wealth's VRTX Position: Q1 2026 in Review

Alaethes Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 4.3% in Q1 2026, buying an estimated $75.5K and bringing the position to 3,949 shares worth $1.76M. The position accounts for 0.5% of the portfolio, ranked #66.

Alaethes Wealth first reported a position in VRTX in Q2 2021 and has held it in 9 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Alaethes Wealth held 3,949 shares of Vertex Pharmaceuticals worth $1.76M as of Q1 2026.
Alaethes Wealth bought 162 Vertex Pharmaceuticals shares in Q1 2026, an estimated $75.5K.
Vertex Pharmaceuticals made up 0.5% of Alaethes Wealth's portfolio in Q1 2026, its #66 holding.
Alaethes Wealth first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 9 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Alaethes Wealth's 13F filing for Q1 2026, filed 12 May 2026.